Johnson & Johnson is engaged in the research, manufacture and sale of medical products, including consumer, pharmaceutical and medical devices.
Johnson & Johnson is a public company. Alex Gorski is Chairman and CEO of Johnson & Johnson and has a 64 approval rating from Owler members. Johnson & Johnson’s most recent acquisition was TARIS Biomedical, LLC for an undisclosed amount in December 2019. Johnson & Johnson has 125 819 subscribers.
Johnson & Johnson’s Competitors, Revenue, Number of Employees, Funding and Acquisitions
Johnson & Johnson top competitors include: Pfizer, Novartis, Merck, AbbVie, Amgen, GSK, Bristol Myers Squibb, AstraZeneca, Roche and Bayer.
Together, they raised over 7.8 billion of their roughly 718.5 thousand employees. Johnson & Johnson has 135,100 employees and is ranked # 1 among the top 10 competitors. The top 10 competitors averaged 65,865.
- Website: jnj.com
- Social Media Links: Twitter Facebook LinkedIn
- Founded: 1886
- Est. Annual Revenue: $82.7B
- Est. Employees: 135,100
- Headquarters: One Johnson & Johnson Plaza New Brunswick, New Jersey 08933
Pfizer is one of Johnson & Johnson’s main competitors. Pfizer is a public company founded in 1849 in New York, New York. Pfizer operates in the pharmaceutical industry. Pfizer employs 46,800 fewer people than Johnson & Johnson.
Novartis is considered one of Johnson & Johnson’s biggest competitors. Novartis was founded in 1996 in Basel, Basel City. Novartis operates in the pharmaceutical industry. Novartis generates $ 34.1 billion less in revenue than Johnson & Johnson.
Merck is Johnson & Johnson’s main competitor. Merck is headquartered in Kenilworth, New Jersey and was founded in 1891. Merck competes in the pharmaceutical field. Merck generates 58% of Johnson & Johnson’s revenues.